Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza
Treatment with a single oral dose of baloxavir led to a lower incidence of transmission of influenza virus to close contacts than placebo. (Funded by F. Hoffmann-La Roche and others; CENTERSTONE ClinicalTrials.gov number, NCT03969212.).
Authors
- Steffen Wildum (ORCID: https://orcid.org/0000-0001-9779-5740)
- Corrado Bernasconi (ORCID: https://orcid.org/0000-0002-1019-5468)
- Laurie Katugampola
- Arnold S. Monto (ORCID: https://orcid.org/0000-0003-3018-435X)
- Takahiro Takazono (ORCID: https://orcid.org/0000-0002-0696-5386)
- Adam S. Lauring (ORCID: https://orcid.org/0000-0003-2906-8335)
- Andreas F. Widmer (ORCID: https://orcid.org/0000-0002-7661-5824)
- Brendan McLean (ORCID: https://orcid.org/0000-0003-1419-8540)
- Klaus Kuhlbusch
- Benjamin J. Cowling (ORCID: https://orcid.org/0000-0002-6297-7154)
- Emily T. Graham (ORCID: https://orcid.org/0000-0001-6696-4564)
- Herman Avner Cohen
- Bin Cao (ORCID: https://orcid.org/0000-0001-8743-2743)
- Aeron C. Hurt (ORCID: https://orcid.org/0000-0001-9731-3481)
- Takashi Kamezawa
Institutions
- Roche (Switzerland) (CH)
- University of Basel (CH)
- University of Michigan (US)
- China-Japan Friendship Hospital (CN)
- Roche (United Kingdom) (GB)
- Nagasaki University (JP)
- University of Hong Kong (HK)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1056/nejmoa2413156
- Citations
- 25
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 33.85
Funders
- Roche
- Biomedical Advanced Research and Development Authority